Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

How Amazon Could Lose Its Healthcare Bid While Drug Distributor Stocks Win

7h seekingalpha (NASDAQ:AMZN) has been one of the most innovative and disruptive companies of this century, with incredible success in areas that lie outside of what has been historically perceived as its core business (book selling). (557-2)

Theravance Biopharma: Johnson & Johnson Deal Looks Solid

2018-02-18 seekingalpha
The deal with JNJ adds even more credibility to the story, and economics of the pact are generous. (11-0)

BioSci Rounds Report For Feb. 16, 2018

2018-02-18 seekingalpha
FDA approved durvalumab (Imfinzi) for the treatment of stage 3 non-small cell lung cancer (without metastasis and are unresectable). (94-0)

It’s Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to Your Watchlist

2018-02-16 investorplace
Just one day after Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) issued some lackluster guidance followed by news that a competing drug had won the FDA’s approval, TEVA stock got an impressive endorsement. Warren Buffett’s Berkshire Hathaway bought $358 million worth of the beaten-down equity during the fourth quarter of last year. (174-0)

MYL / Mylan N.V. - Stock Institutional Ownership and Shareholders -

Mylan N.V. (NASDAQ:MYL) has 486 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 410,430,354 shares. Largest shareholders include Wellington Management Group Llp, BlackRock Inc., Vanguard Group Inc, Pzena Investment Management Llc, State Street Corp, Invesco Ltd., Paulson & Co. Inc., GreenLight Capital Inc, Goldman Sachs Group Inc, and First Pacific Advisors, LLC. (107-1)

Fresenius: Proven Value Creation Amidst M&A Doubts

2018-01-20 seekingalpha
Shares of Fresenius trade at a discount to peers after the market has doubted the firm's M&A prowess in light of a troubled Akorn acquisition. (103-1)

2017 Portfolio Performance Review - A Tale Of 2 Halves

2018-01-02 seekingalpha
2017 was a strong year for my portfolio, returning 26.37% versus the S&P 500s 20.37% return. (766-1)

Stocks To Watch: Automakers Rev Up For 2018

2017-12-31 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning. (629-4)

How Pfizer Inc. Stock Is Positioning for Solid Growth Ahead

2017-12-28 investorplace
Pfizer Inc. (NYSE:PFE) looks like an ideal investment for value investors in PFE stock. Its share trade at a 13x forward P/E and the company pays out a dividend yielding over 3.75 percent. After returning a decent 11 percent return in 2017, chances are good that the company will reward its investors again in the coming year. (314-0)

GlaxoSmithKline: Dividend Risk Brings Opportunity

2017-12-19 seekingalpha
The current dividend pay-out ratio and generic risk to one of its blockbuster drugs has the market spooked. (8-0)

Your Daily Pharma Scoop: Dynavax Beyond Heplisav-B, Novartis' Cosentyx, Shire Granted ODD

2017-12-01 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (155-0)

Could The FDA's Less Stringent Regulations Help MannKind?

2017-11-30 seekingalpha
FDA Commissioner recently issued new guidance, making it easier for generics competing against EpiPen to gain approval. (76-0)

Your Daily Pharma Scoop: Omeros If And Buts, Egalet's Oxycodone Success, Auris Flunks Study

2017-11-29 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (429-2)

Biotech Analysis Central Pharma News: Regeneron's Flop, Viking's Trial Success, Biogen's MS Deal

2017-11-29 seekingalpha
Regeneron Pharmaceuticals fails a phase 2 combo study in both Wet AMD and diabetic macular edema. (148-0)

Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%

2017-11-28 zacks
Teva Pharmaceutical Industries Limited’s (TEVA - Free Report) new chief executive officer, Kare Schultz announced a new organizational and leadership structure to save costs and increase productivity. The organizational changes that include the departure of heads of three divisions will be effective immediately. (217-1)

CUSIP: N59465109